Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zibotentan 10 mg in non-metastatic hormone-resistant prostate cancer
DRKS00003883Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 39
01
Overview
Phase 3, randomised, double-blind trial in castration-resistant prostate cancer (CRPC) comparing Zibotentan 10 mg once daily with Placebo once daily (2 arms). Started Apr 2012; status: terminated.
02
Drugs
zibotentan
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on DRKS00003883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00003883.